Methods of treating complement-associated disorders with anti-C5a antibodies
First Claim
1. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds C5a, wherein the antibody, or antigen-binding fragment thereof, comprises complementarity determining regions (CDRs) of a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO:
- 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
42.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture'"'"'s syndrome, and chronic obstructive pulmonary disease.
-
Citations
14 Claims
-
1. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds C5a, wherein the antibody, or antigen-binding fragment thereof, comprises complementarity determining regions (CDRs) of a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO:
- 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
42. - View Dependent Claims (9, 10, 11, 12, 13, 14)
- 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
-
2. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:
- 20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47.
- 20;
-
3. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the antibody, or antigen-binding fragment thereof, comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:
- 45 and the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
42.
- 45 and the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
-
4. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the isolated antibody, or antigen-binding fragment thereof, that binds human C5a, comprises heavy and light chains, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO:
- 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO;
40.
- 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO;
-
5. A method for treating graft-versus-host disease (GVHD), the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds C5a, wherein the antibody, or antigen-binding fragment thereof, comprises complementarity determining regions (CDRs) of a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO:
- 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
42.
- 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
-
6. A method for treating graft-versus-host disease (GVHD), the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:
- 20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47.
- 20;
-
7. A method for treating graft-versus-host disease (GVHD), the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the antibody, or antigen-binding fragment thereof, comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:
- 45 and the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
42.
- 45 and the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
-
8. A method for treating graft-versus-host disease (GVHD), the method comprising administering to a human in need thereof, an isolated antibody, or antigen-binding fragment thereof, that binds human C5a, wherein the isolated antibody, or antigen-binding fragment thereof, that binds human C5a, comprises heavy and light chains, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO:
- 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO;
40.
- 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO;
Specification